Stocks & Investing
Tue, September 24, 2024
[ 12:00 AM ] - WOPRAI
Mon, September 23, 2024
[ 12:00 AM ] - WOPRAI
Wed, August 14, 2024
[ 12:00 AM ] - WOPRAI
Wed, June 12, 2024
[ 12:00 AM ] - WOPRAI
Thu, March 28, 2024
[ 12:00 AM ] - WOPRAI
Wed, March 27, 2024
[ 12:00 AM ] - WOPRAI
Tue, February 20, 2024
[ 12:00 AM ] - WOPRAI
Mon, November 13, 2023
[ 12:00 AM ] - WOPRAI
Fri, October 6, 2023
[ 12:00 AM ] - WOPRAI
Mon, August 14, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
Wed, December 7, 2022
[ 12:00 AM ] - WOPRAI
Wed, November 24, 2021
[ 12:00 AM ] - WOPRAI
Fri, May 28, 2021
Thu, March 11, 2021
[ 12:00 AM ] - WOPRAI
Fri, February 12, 2021
[ 12:00 AM ] - WOPRAI
Wed, April 11, 2018 Jonathan Aschoff Maintained (zvra) at Strong Buy with Increased Target to $21 on, Sep 24th, 2024
Jonathan Aschoff of Roth MKM, Maintained "Zevra Therapeutics, Inc." (ZVRA) at Strong Buy with Increased Target from $19 to $21 on, Sep 24th, 2024.
Jonathan has made no other calls on ZVRA in the last 4 months.
There are 3 other peers that have a rating on ZVRA. Out of the 3 peers that are also analyzing ZVRA, 0 agree with Jonathan's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Jonathan
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $20 on, Friday, September 20th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $22 on, Wednesday, September 18th, 2024
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy on, Wednesday, August 14th, 2024
